Mumbai: Remedium Lifecare Limited, a pivotal player in India’s pharmaceutical industry, has clinched a noteworthy contract with a UK-based pharmaceutical distribution firm, promising to amplify its stature in the global market.
The landmark agreement, valued at ₹182 crore, is a game-changer for Remedium, sparking substantial excitement in the Indian stock market. Market analysts anticipate the deal could result in a 100% increase in Remedium’s stock value, given its competitive price-to-earnings ratio of 11, compared to the pharmaceutical sector’s average of 60.
Boasting zero debt and a robust 65% promoter holding, Remedium’s financial health remains robust. With operations in 27 countries, debt-free manufacturing, and state-of-the-art facilities, the company is poised for future success. However, compliance with regulatory standards remains a pivotal factor for reaping the full benefits of this lucrative partnership.
